content_image/928303.jpg content_image/928306.jpg content_image/928304.jpg content_image/928305.jpg
<img src='content_image/928303.jpg'>

The test method followed was according to European Stan› dard EN 13704: Quantitative Suspension Test for the Evalu› ation of Sporicidal Activity of Chemical Disinfectants and Antiseptics Used in Food, Industrial, Domestic and Institu› tional Areas. Generally, a test suspension of bacterial spores in a solution of interfering substance, simulating clean con› ditions, was added to a prepared sample of the test formula› tion diluted in hard water. The mixture was maintained at the specific temperature and time desired. At this contact time, an aliquot is taken; the sporicidal action in this portion was immediately neutralized or suppressed by a validated method. The number of surviving bacterial spores in each sample was determined and the reduction in viable counts was calculated. 

The disinfectant properties of each of the formulations at 5 minutes at 40° C. are shown below in Table 12. 

<img src='content_image/928306.jpg'>

As can be seen from this table, the compositions of the present invention that were tested were as effective as a dis› infectant as the commercially available formulations tested. Further, with respect to Clostridium difficile, the composi› tions of the present invention were more effective than the commercially available products tested. 

(b) Stability and Sporicidal Efficacy at 14 Days 

A test was run to determine the stability and sporicidal efficacy of a composition of the present invention against spores. The composition tested included the sulfonated per› oleic acid product, and an amount of peroxyoctanoic acid. The test method used was the European Standard EN 13704: Quantitative Suspension Test for the Evaluation ofSporicidal Activity of Chemical Disinfectants and Antiseptics Used in Food, Industrial, Domestic and Institutional Areas, described above. The table below shows the results of this study. 

<img src='content_image/928304.jpg'>

A composition including 30 ppm peroxyoctanoic acid was also tested. The composition of peroxyoctanoic acid alone did not result in a reduction. 

FIG. 5 shows the stability impact that the compound of the present invention used, i.e., the sulfonated peroleic acid prod› uct, had on the amount of POOA over time during this study. As can be seen from this figure, the amount of POOA avail- able over time was higher with the sample of POOA that was stabilized using a composition of the present invention, com› pared to a sample of POOA that was not stabilized using a composition of the present invention. 

( c) Synergistic Effect of a Composition of the Present Invention with a Known Sanitizes 

For this study, the ASME 1052-96: Standard Test Method for Efficacy of Antimicrobial Agents against Viruses in Sus› pension was used. A composition including 1000 ppm per› oxyacetic acid (POAA) was tested alone, and in combination with sulfonated peroleic acid product. 

The POAA solution alone did not display complete inac› tivation of Poliovirus Type 1 after an exposure time of four minutes. The reductions in viral titer were s0.75 and s0.50 log 10. When the POAA solution was tested with 1000 ppm of the sulfonated peroleic acid product, the solution displayed complete inactivation of Poliovirus Type 1 after an exposure time of a few minutes, and was therefore efficacious against the virus. The reduction in viral titer was ;;:.5.75 log 10. 

( d) Synergistic Effect of a Compound of the Present Inven› tion with Peroxyoctanoic Acid 

For this study, the MS103: Quantitative Tuberculocidal Test was used. The sulfonated peroleic acid product was tested alone, and in combination with peroxyoctanoic acid at various concentrations against Mycobacterium bovis BCG. The compositions were tested at a pH of 6.5 at room tempera› ture. The results are shown in the table below. 

<img src='content_image/928305.jpg'>

As can be seen from this table, the samples treated with both a composition of the present invention including the sulfonated peroleic acid product, and POOA had a higher log reduction of Mycobacterium bovis BCG than those samples treated with either the sulfonated peroleic acid product or POOA alone. Although it was found that the samples treated 

